Compare RNR & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RNR | RDY |
|---|---|---|
| Founded | 1993 | 1984 |
| Country | Bermuda | India |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.3B | 11.6B |
| IPO Year | 1995 | N/A |
| Metric | RNR | RDY |
|---|---|---|
| Price | $266.10 | $14.19 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 1 |
| Target Price | ★ $291.73 | $16.90 |
| AVG Volume (30 Days) | 387.6K | ★ 938.9K |
| Earning Date | 10-28-2025 | 01-22-2026 |
| Dividend Yield | ★ 0.60% | 0.50% |
| EPS Growth | N/A | ★ 9.95 |
| EPS | ★ 34.70 | 0.79 |
| Revenue | ★ $12,214,870,000.00 | $3,851,623,984.00 |
| Revenue This Year | N/A | $6.16 |
| Revenue Next Year | N/A | $2.57 |
| P/E Ratio | ★ $7.63 | $17.87 |
| Revenue Growth | N/A | ★ 14.10 |
| 52 Week Low | $219.00 | $12.26 |
| 52 Week High | $290.78 | $16.17 |
| Indicator | RNR | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 54.79 | 57.67 |
| Support Level | $261.38 | $13.64 |
| Resistance Level | $263.87 | $14.20 |
| Average True Range (ATR) | 5.15 | 0.16 |
| MACD | 0.09 | 0.05 |
| Stochastic Oscillator | 64.18 | 98.25 |
RenaissanceRe Holdings Ltd provides reinsurance and insurance solutions and related services. The company's core products include property, casualty and specialty reinsurance. Revenue is derived from three sources: net premiums earned from the insurance and insurance products sold; net investment income from the investment of capital funds and cash; and other income from the company's joint ventures, advisory services, and other items. The reportable segments of the company are the Property segment which includes catastrophe and other property reinsurance, and the Casualty and Specialty segment which is comprised of casualty and specialty reinsurance. It derives a majority of its revenue from the Casualty and specialty segment.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.